CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,617 enrolled
Drug / intervention
Tiotropium + Olodaterol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04011475
NCT04011475N/ACompleted
CompareCT.gov

Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim·observational·Posted Jul 8, 2019·Updated Jun 14, 2022

In Brief

An observational study evaluating Tiotropium + Olodaterol, Other LABA/LAMA, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,617 participants across 12 sites.

Detailed Summary

Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or LAMA treatment

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 8, 2019
Enrollment StartDec 29, 2019
Primary CompletionOct 31, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.0 years ago

Interventions

Tiotropium + Olodateroldrug

Spiolto®

Other LABA/LAMAdrug

tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium

LAMAdrug

aclidinium bromide, glycopyrronium, tiotropium, umeclidinium